Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price [Yahoo! Finance]
Virpax Pharmaceuticals, Inc. (VRPX)
Company Research
Source: Yahoo! Finance
in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that it will effect a 1-for-10 reverse stock split ("reverse split") of its common stock, par value $0.001 per share ("Common Stock"), that will become effective at 12:01 a.m. Eastern Time on March 1, 2024. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "VRPX" and will begin trading on a split-adjusted basis when the Nasdaq opens on March 1, 2024 ("Effective Time"). The new CUSIP number for the Common Stock following the reverse split will be 928251206. At a special meeting of stockholders held on December 28, 2023 (the "Special Meeting"), the Company's stockholders granted the Company's Board of Directors the discretion to effect a reverse stock split of the Company's Common Stock at a ratio of not less than 1-for-2 and not more than 1-for-20, w
Show less
Read more
Impact Snapshot
Event Time:
VRPX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRPX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRPX alerts
High impacting Virpax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
VRPX
News
- Virpax Pharmaceuticals Reports 2023 Year-End Results [Yahoo! Finance]Yahoo! Finance
- Virpax Pharmaceuticals Reports 2023 Year-End ResultsBusiness Wire
- Scilex Holding Company's Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of SAcquire Media Monitor
- Scilex and Sorrento settle with Virpax and its founder Anthony Mack [Seeking Alpha]Seeking Alpha
- Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc. [Yahoo! Finance]Yahoo! Finance
VRPX
Sec Filings
- 4/26/24 - Form S-1/A
- 4/18/24 - Form S-1
- 4/5/24 - Form S-8
- VRPX's page on the SEC website